Bio Usawa and Nanoly Bioscience Forge $500 Million Agreement

On February 17, 2026, Bio Usawa and Nanoly Bioscience announced a significant licensing agreement valued at up to $500 million for the use of DynaShieldTM technology. This collaboration grants Bio Usawa exclusive, worldwide rights to utilize and sublicense the DynaShieldTM technology across its product range and third-party biologics and vaccines. With this agreement, both companies aim to enhance global access to essential biopharmaceuticals by addressing the challenges associated with traditional cold chain logistics.

Typically, the storage and transportation of biologics necessitate a continuous “cold chain,” a temperature-controlled supply chain often difficult to maintain in various regions. The DynaShieldTM technology, developed by Nanoly Bioscience, employs a specialized polymer scaffold designed to protect sensitive proteins from thermal degradation. This innovation allows critical medical products to remain stable outside of refrigeration for longer periods, overcoming a major barrier to health equity.

Transforming Access to Biologics

Dr. Menghis Bairu, CEO of Bio Usawa, expressed confidence in the technology’s potential to transform the healthcare landscape. “Our mission is to make biologics affordable and accessible,” he stated. “By eliminating the cold chain requirement through this technology, we are removing the single greatest logistical barrier to health equity. This $500 million investment reflects our confidence that this technology will redefine global drug access.”

Dr. Balaji Sridhar, CEO of Nanoly Bioscience, echoed this sentiment, emphasizing Bio Usawa’s alignment with their vision. “Bio Usawa is the ideal partner to take the DynaShieldTM technology to the global stage,” he commented. “Their manufacturing scale and commitment to underserved markets align perfectly with our vision of a world where access to life-saving medicine isn’t limited by the reach of a refrigerator.”

Impact on Global Health and Cost Reduction

This partnership is anticipated to significantly reduce the overhead costs associated with the distribution of biologics and vaccines. Currently, the World Health Organization estimates that up to 50 percent of vaccines are wasted globally each year, largely due to failures in the cold chain and logistics issues. The DynaShieldTM technology could greatly mitigate these losses, enabling room-temperature stability that would allow for more reliable access to vital therapies, especially in regions lacking robust refrigeration infrastructure.

Additionally, industry analyses suggest that cold-chain failures and temperature excursions cost the biopharmaceutical sector between $20 billion and $35 billion annually. This includes losses from spoiled products, reshipment costs, and compliance issues, according to reports from the IQVIA Institute for Human Data Science and various industry logistics sources. By enhancing stability and reducing wastage, DynaShieldTM could play a crucial role in lowering distribution costs and improving health outcomes worldwide.

Bio Usawa, headquartered in San Francisco, is focused on the manufacturing and distribution of high-quality biosimilars and essential biologics. The company aims to bridge healthcare accessibility gaps in emerging markets through innovation and localized production. Nanoly Bioscience, based in Los Angeles, specializes in the stabilization of high-value biologics, with the DynaShieldTM platform engineered to ensure efficacy from production to point of care.

This collaboration represents a pivotal step towards enhancing global health equity and improving the efficiency of biopharmaceutical distribution, with the potential to change the landscape of vaccine and biologic access worldwide.

For media inquiries, please contact the Press Office at Bio Usawa at [email protected] or call +1 (555) 012-3456. For investor relations, reach out to [email protected].